Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a patch of your own retina restore clearer vision?

NCT ID NCT07767539

Disease control Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 17, 2026 · Last updated Aug 19, 2026 · Updated 2 times

Summary

This trial tests a new surgical technique for people with an epiretinal membrane, a condition where abnormal tissue grows on the retina and blurs or distorts vision. The standard treatment is to peel off this membrane, but the retina may not fully heal. The new approach uses a small piece of the patient's own retinal tissue to cover the area after removal, aiming to promote more natural healing. Participants will be randomly assigned to receive either the new technique or standard surgery, and their vision and retinal structure will be monitored over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A surgical procedure using a patient's own internal limiting membrane (ILM) patch to cover the macula after epiretinal membrane removal.
What this could lead to
If successful, this technique could improve visual recovery and restore the retina's normal structure better than standard surgery for epiretinal membrane.
What could go wrong
This is a relatively new surgical approach, and its benefits over standard peeling are not yet proven. Risks include surgical complications and the possibility that the patch may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of epiretinal membrane confirmed by Spectral-domain Optical Coherence Tomography * Best corrected visual acuity \<= 0.8 (equivalent to 0.1 LogMAR) * Presence of metamorphopsia confirmed by Amsler grid testing * Ability to understand the study information and provide written informed consent voluntarily Exclusion Criteria: * History of intraocular surgery, with the exception of uncomplicated cataract surgery * Presence of any of the following ocular diseases: retinal vascular diseases (including diabetic retinopathy, retinal hemangioma, retinal vascular occlusion, Coats' disease, etc.), uveitis, macular degeneration, macular hole, retinal detachment, retinoschisis, pathologic myopia, ocular trauma, intraocular tumor and neurofibromatosis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Idiopathic epiretinal membrane are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

preretinal fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Idiopathic epiretinal membrane

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.